Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 12.77 is 34% above its 5-year average of 9.53, around the middle of its 5-year range (5.17–16.22).
As of the fiscal period ended Tuesday, June 30, 2026. 7.63% above its 12-month average of 11.86.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.77.
CURRENT RATIO
12.77
CURRENT RATIO AVG TTM
11.86
CURRENT RATIO AVG 3Y
10.06
CURRENT RATIO AVG 5Y
9.53
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+7.63%
CURRENT VS 3Y AVG
+26.89%
CURRENT VS 5Y AVG
+33.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.59
median of 793 covered companies
CURRENT VS SECTOR MEDIAN
+255.71%
vs the sector median at left
AbCellera Biologics Inc.
Market Cap
$4.08B
Current Ratio
12.77
TTM Avg
11.86
3Y Avg
10.06
5Y Avg
9.53
Market Cap
$4.03B
Current Ratio
18.27
TTM Avg
19.28
3Y Avg
20.00
5Y Avg
29.44
Market Cap
$4.28B
Current Ratio
16.24
TTM Avg
19.89
3Y Avg
20.20
5Y Avg
22.94
Market Cap
$4.40B
Current Ratio
0.84
TTM Avg
0.80
3Y Avg
0.95
5Y Avg
1.27
Market Cap
$4.41B
Current Ratio
4.79
TTM Avg
3.12
3Y Avg
4.00
5Y Avg
4.41
Market Cap
$4.43B
Current Ratio
5.08
TTM Avg
3.83
3Y Avg
4.06
5Y Avg
4.06
Market Cap
$3.60B
Current Ratio
1.42
TTM Avg
24.66
3Y Avg
24.23
5Y Avg
16.18
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $4.08B | 12.77 | 11.86 | 10.06 | 9.53 |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.03B | 18.27 | 19.28 | 20.00 | 29.44 |
| LivaNova PLC (LIVN)vs › | $4.15B | 1.45 | 2.12 | 2.54 | 2.24 |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 2.43 | 2.47 | 2.49 | 3.30 |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.28B | 16.24 | 19.89 | 20.20 | 22.94 |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.40B | 0.84 | 0.80 | 0.95 | 1.27 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | 4.79 | 3.12 | 4.00 | 4.41 |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.43B | 5.08 | 3.83 | 4.06 | 4.06 |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.60B | 1.42 | 24.66 | 24.23 | 16.18 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | 3.87 | 5.22 | 3.96 | 4.18 |
Current Ratio
12.77
Quick Ratio
12.63
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 12.77 |
| 2026-03-31 | 14.05 |
| 2025-12-31 | 11.32 |
| 2025-09-30 | 10.10 |
| 2025-06-30 | 11.07 |
| 2025-03-31 | 10.15 |
| 2024-12-31 | 9.81 |
| 2024-09-30 | 9.34 |
| 2024-06-30 | 10.96 |
| 2024-03-31 | 7.76 |
| 2023-12-31 | 7.33 |
| 2023-09-30 | 8.34 |
| 2023-06-30 | 7.83 |
| 2023-03-31 | 10.50 |
| 2022-12-31 | 8.67 |
| 2022-09-30 | 9.86 |
| 2022-06-30 | 5.17 |
| 2022-03-31 | 5.50 |
| 2021-12-31 | 7.70 |
| 2021-09-30 | 16.22 |
| 2021-06-30 | 12.39 |
| 2021-03-31 | 10.27 |
| 2020-12-31 | 7.86 |
| 2020-09-30 | 5.67 |
| 2020-06-30 | 7.04 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 1.60 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
